Get the Stockscreener App
0.00
100.00%
-11.13
After Hours:
11.20
11.20
+
Verve Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
See More
Previous Close:
$11.13
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$994.04M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
0.00
EPS:
-2.59
Net Cash Flow:
$-134.39M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$11.40
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
(978) 501-3026
Address
201 BROOKLINE AVENUE, BOSTON
Compare VERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
0.00 | 994.04M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Apr-08-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-15-22 | Initiated | Goldman | Sell |
| Oct-06-22 | Initiated | Credit Suisse | Neutral |
| Aug-25-22 | Upgrade | Stifel | Hold → Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Jul-12-21 | Initiated | Guggenheim | Buy |
| Jul-12-21 | Initiated | JP Morgan | Neutral |
| Jul-12-21 | Initiated | Jefferies | Buy |
| Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
Verve Therapeutics Inc. stock trend forecastGlobal Markets & Accurate Trade Setup Notifications - Newser
Understanding Verve Therapeutics Inc.’s price movement2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - Newser
Will Verve Therapeutics Inc. benefit from macro trendsSell Signal & Smart Allocation Stock Tips - Newser
Will Verve Therapeutics Inc. outperform the market2025 Dividend Review & Accurate Buy Signal Alerts - Newser
Is Verve Therapeutics Inc. stock a good hedge against inflationPortfolio Value Summary & Weekly Consistent Profit Watchlists - Newser
Signal strength of Verve Therapeutics Inc. stock in tech scannersRate Hike & AI Driven Stock Reports - Newser
What’s next for Verve Therapeutics Inc. stock priceTrade Signal Summary & Real-Time Volume Triggers - Newser
Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102 - MSN
Heatmap analysis for Verve Therapeutics Inc. and competitorsDip Buying & Long-Term Safe Return Strategies - Newser
Visual trend scoring systems applied to Verve Therapeutics Inc.July 2025 Weekly Recap & Technical Analysis for Trade Confirmation - Newser
What moving averages say about Verve Therapeutics Inc.July 2025 Breakouts & Long-Term Safe Investment Ideas - Newser
Verve Therapeutics Inc. stock chart pattern explainedJuly 2025 Catalysts & Community Trade Idea Sharing Platform - Newser
Does Verve Therapeutics Inc. fit your quant trading modelEarnings Growth Report & Risk Adjusted Buy/Sell Alerts - Newser
Published on: 2025-08-29 21:34:59 - Newser
Candlestick signals on Verve Therapeutics Inc. stock todayWeekly Trading Summary & Safe Entry Momentum Stock Tips - Newser
What to expect from Verve Therapeutics Inc. in the next 30 daysProduct Launch & Low Risk Investment Opportunities - Newser
Analyzing Verve Therapeutics Inc. with multi timeframe chartsJuly 2025 WrapUp & Low Volatility Stock Suggestions - Newser
News impact scoring models applied to Verve Therapeutics Inc.July 2025 Setups & AI Forecast Swing Trade Picks - Newser
Real time breakdown of Verve Therapeutics Inc. stock performance2025 Performance Recap & Verified Trade Idea Suggestions - Newser
Predicting Verve Therapeutics Inc. trend using moving averages2025 Breakouts & Breakdowns & Weekly Chart Analysis and Trade Guides - Newser
Pattern recognition hints at Verve Therapeutics Inc. upsideJuly 2025 Setups & Trade Opportunity Analysis Reports - Newser
Verve Therapeutics Inc Stock (VERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):